Opthea today announced the successful completion of the institutional component of the capital raising announced on Wednesday, 12 June 2024. To read full press release: opthealimited.gcs-web.com/news-releases/… #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation

In this month’s Retina Today edition, Fred Guerard, Opthea CEO, and a panel of retina experts discuss the potential of sozinibercept (OPT-302) to transform the wet AMD treatment landscape and address the unmet medical need for improved efficacy. Please click here to read the

Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens Opthea is pleased to announce that the fully underwritten Retail Entitlement Offer opens at 9:00 am (Melbourne time) on 19 June 2024. The Retail Entitlement Offer, which will raise approximately A$55.0 million (US$36.9

Overcoming the Wet AMD treatment gap Check out the recent article by Rahul N. Khurana, MD, published in Modern Retina The article highlights the need for better visual outcomes in wet AMD patients, and takes a closer look at potential reasons for suboptimal results with

New Publication: VEGF-C and -D Signaling Pathways as Potential Targets for the Treatment of Wet AMD In this month’s edition of Ophthalmology and Therapy, a scientific review was published about the growing body of evidence that in retinal diseases, such as wet AMD, the

Taneen Hisgrove, Senior Director, Clinical Operations at Opthea recognized for her clinical trial industry expertise and site advocate, will act as a Site Spark Judge, plenary and breakout session facilitator at The Australia-New Zealand Site Solutions Summit in Melbourne July

Opthea today announced the successful completion of the fully underwritten retail component (Retail Entitlement Offer) of its 1 for 1.22 pro-rata accelerated non-renounceable entitlement offer (Entitlement Offer) of new fully paid ordinary shares in Opthea (New Shares) which

Opthea today announced the formation of its Medical Advisory Board (MAB) composed of 10 retina thought leaders from around the world. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB’s role is to advise the Company on opportunities to address

This story is a great summary of the most recent Opthea highlights. A big thank you to the editors of Eyes On Eyecare for sharing this article. glance.eyesoneyecare.com/stories/2024-0… Eyes On Eyecare - Ophthalmology #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma

Opthea will present at the PEAK Monsoon Biotech Showcase event in Melbourne, Australia, on August 21, 2024. Dr. Megan Baldwin, Founder, CIO and Executive Director, Opthea, will showcase the Company’s pipeline and business case as one of eight leading biotech companies in

Thank you Dr Steinle and Modern Retina for sharing this important data.

Thank you Dr Steinle and Ocular Surgery News for sharing this important data.

Frederic Guerard, PharmD, CEO Opthea, will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024. The webcast will be accessible both via the link: journey.ct.events/view/bc8c5e95-… and on the “Events &

Frederic Guerard, PharmD, CEO Opthea, will present at the H.C. Wainwright 26th Global Investment Conference on September 9, 2024, and the Cantor 2024 Global Healthcare Conference on September 17, 2024. Management will participate in one-on-one investor meetings at both

Interesting read about bringing a personal touch to patient care and providing eligible patients with access to cutting-edge advancements with the chance for better visual outcomes. eyesoneyecare.com/resources/expa… #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology

Opthea Announces Executive Leadership Changes and Senior Hires Opthea today announced executive leadership changes in Financeand Commercial as well as senior hires for Biometrics, Clinical Operations and Market Access. These organizational changes further deepen the company’s

Opthea to participate in the Retina Society 57th Annual Scientific Meeting We look forward to seeing you at the Opthea booth #8 at the Retina Society 57th Annual Scientific Meeting in Lisbon, September 11-15, 2024. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology

Opthea to have significant presence at the 24th EURETINA congress and EURETINA Innovation Spotlight Join us for presentations by retina thought leaders featuring sozinibercept’s mechanism of action, the design of the on-going Phase 3 trials, as well as further insights into

Opthea today announced the completion of its drug substance Process Performance Qualification (PPQ) campaign of sozinibercept. The PPQ campaign consisted of the production of three successful consecutive commercial-scale drug substance batches required for the validation of